Current Report Filing (8-k)
November 09 2016 - 9:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 9, 2016
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36508
|
|
27-1524986
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
|
|
2225 Colorado Avenue
Santa Monica, California
|
|
90404
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (310) 824-9999
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2016, Kite Pharma, Inc. (“Kite”) announced its financial results for the third quarter ended September 30, 2016 in the press release
attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02, including the attached Exhibit 99.1, is
being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing made by Kite under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits.
The following exhibit is filed as
part of this Current Report:
|
|
|
|
|
99.1
|
|
Press Release of Kite, dated November 9, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Date: November 9, 2016
|
|
|
|
KITE PHARMA, INC.
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Paul Jenkinson
|
|
|
|
|
|
|
|
Name: Paul Jenkinson
|
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
EXHIBIT INDEX
|
|
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release of Kite, dated November 9, 2016.
|
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2023 to Apr 2024
